Status:
RECRUITING
Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer
Lead Sponsor:
Shanghai Proton and Heavy Ion Center
Conditions:
Pancreatic Cancer Non-resectable
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The aim of this study is to investigate the clinical efficacy and safety of ablative carbon ion radiotherapy for locally advanced unresectable pancreatic cancer with pencil beam scanning and simultane...
Detailed Description
The aim of this study is to investigate the clinical efficacy and safety of ablative carbon ion radiotherapy for locally advanced unresectable pancreatic cancer using pencil beam scanning and simultan...
Eligibility Criteria
Inclusion
- Have the ability to sign the written informed consent;
- Ductal adenocarcinoma of the pancreas confirmed by histopathology or cytopathology;
- Distant metastasis was excluded by imaging assessment (PET-CT, cranial MRI), and was defined as locally advanced unresectable according to NCCN Guidelines Version 2022.1, that is, T4N0-2M0, Stage III (AJCC/UICC Version 8);
- The maximum diameter of pancreatic primary lesion and positive lymph node ≤7cm;
- Pancreas primary lesion or positive lymph node did not invade digestive tract (stomach, duodenum and small intestine);
- Eastern Cooperative Oncology Group (ECOG) performance score 0-1;
- Adequate bone marrow function (neutrophil count ≥1.5×109/L, platelet count ≥100×109/L, hemoglobin ≥10.0g/dL);
- Adequate liver function (total bilirubin \<1.5 times the upper limit of normal value, aminotransferase \<2.5 times the upper limit of normal value);
- Adequate renal function (serum creatinine \<2mg/dL, or creatinine clearance \>50mL/min).
Exclusion
- Multiple primary pancreatic lesions (\>1);
- Tumor invaded the adjacent digestive tract;
- Radiation therapy history;
- Other local treatments history for pancreatic cancer, such as HIFU and irreversible electroporation;
- The irradiation dose of organs at risk cannot reach the dose constraint;
- Other malignant tumors history;
- Inability to understand the purpose of treatment or unwillingness/inability to sign informed consent.
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT05424159
Start Date
July 1 2022
End Date
December 1 2026
Last Update
December 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Proton and Heavy Ion Center
Shanghai, China, 201315